1. Home
  2. BNTX vs ILMN Comparison

BNTX vs ILMN Comparison

Compare BNTX & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNTech SE

BNTX

BioNTech SE

N/A

Current Price

$81.14

Market Cap

22.9B

Sector

Health Care

ML Signal

N/A

Logo Illumina Inc.

ILMN

Illumina Inc.

N/A

Current Price

$195.59

Market Cap

37.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNTX
ILMN
Founded
2008
1998
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
37.0B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
BNTX
ILMN
Price
$81.14
$195.59
Analyst Decision
Buy
Buy
Analyst Count
21
21
Target Price
$112.22
★ $261.45
AVG Volume (30 Days)
911.0K
★ 2.0M
Earning Date
11-03-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 170.87
EPS
N/A
★ 3.65
Revenue
N/A
★ $4,343,000,000.00
Revenue This Year
N/A
$6.61
Revenue Next Year
N/A
$7.00
P/E Ratio
★ N/A
$54.95
Revenue Growth
★ N/A
N/A
52 Week Low
$79.81
$112.65
52 Week High
$124.00
$309.35

Technical Indicators

Market Signals
Indicator
BNTX
ILMN
Relative Strength Index (RSI) 32.23 36.11
Support Level $79.81 $200.01
Resistance Level $93.48 $201.83
Average True Range (ATR) 2.46 12.07
MACD -0.23 -2.60
Stochastic Oscillator 5.40 8.35

Price Performance

Historical Comparison
BNTX
ILMN

About BNTX BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: